PRESS ARCHIVE ROOM | PRESS ARCHIVE ROOM Just click on the publication of interest. Attention Virginia Alpha's Please Support Comprehensive Clean Indoor Air Legislation Let's clear the air in Virginia: Clean Air Bill American Transplant Congress 2003: The Fourth Joint American Transplant Meeting Tolerogenic Protocol Reduces Immunosuppressive Drugs After Lung Transplant ZLB Behring: Medicare proposals affecting clotting factors, IVIG & Alpha-1 therapies Aventis Behring--Receives FDA Approval for Zemaira Aventis Behring--announce the selection of Accredo Health, Incorporated as the exclusive specialty provider of Zemaira. CSL Completes Acquisition of Aventis Behring Baxter : Baxter Healthcare has responded with the following letter to patients, concerning Alpha 1 Foundation statement. Baxter Healthcare has responded with the following letter to Healthcare Professionals, concerning Alpha 1 Foundation statement. Data Presented Show Treatment with Baxter's ARALAST May Positively Impact Life Expectancy in Patients with Hereditary Emphysema Sample Program for ARALAST Baxter - Free Sample Program for Aralast extended! Baxter -- Facts on Aralast. Baxter - New Alternative for Alpha-1 Patients. Baxter - Completes acquisition of Aralast from Alpha Therapeutic Corporation Baxter - Letter to Alpha-1 community "Baxter has completed its acquisition of all manufacturing and distribution rights to ARALAST." Talecris (Bayer) Corporation: Bayer Corporation Announces Intent to Sell Biological UPDATE 2-Embattled Bayer to sell plasma business Bayer BP Sterile Filling Facility Receives Additional Regulatory Approvals Bayer Sells Plasma Unit to U.S. Investors Chiron Corporation: Chiron Receives FDA Priority Review Designation for New Drug Application for PULMINIQ --Cyclosporine, USP-- Inhalation Solution GTC Biotherapeutics, Inc. : GTC's recombinant form of human antithrombin - Alpha-1 Antitrypsin Federal Government Agencies Press Release: FDA - Labeling Changes for Drug Products that Contain Salmeterol Senate OKs Ban on Genetic Discrimination - Feb 18, 2005 FDA calls off gene therapy experiments... NIH Establishes Rare Diseases Clinical Research Network Kamada Ltd: FDA awards exclusivity to Kamada drug Kamada has developed a treatment for congenital emphysema Stanford University Medical Center: Radically New Anti-rejection Drug Shown To Offer Safe Control Of Immune System In Stanford Study University of Vermont College of Medicine Stem Cells Shown To Regenerate Damaged Lung Tissue Return Home | Press Archives | Press Room Alpha-1 Advocacy Alliance, PO Box 202, 103 Rapidan Church Lane, Wolftown, VA 22748 Telephone: 540-948-6777 or 1-866-FOR-A1AA   (1-866-367-2122) Fax # 540-948-6763 Copyright © 2005 Alpha-1 Advocacy Alliance, All Rights Reserved Home | Disclaimer | Privacy Policy